Feature | October 02, 2013

FDA Offers Draft of Updated Engineering Tests for Stents, Delivery Systems

stents cath lab FDA update guidance delivery system

October 2, 2013 — The U.S. Food and Drug Administration (FDA) released a draft of its proposed updates for the non-clinical engineering tests and recommended labeling for intravascular stents and associated delivery systems. It is designed to provide draft guidance for industry and FDA staff.

FDA has developed a guidance to inform the coronary and peripheral stent industry about selected updates to FDA’s thinking regarding certain non-clinical testing for these devices.  While FDA is in the process of making more substantial updates to the Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems guidance, it is issuing a “short guidance update” on select sections in order to notify the industry in a timely manner of its revised recommendations. 

Section III of the guidance provides cross-reference and updates to the related sections of the existing guidance.  Following the close of the comment period on this guidance, FDA intends to consider the comments received, revise this guidance as appropriate and publish it in final.  Simultaneously, FDA will issue an update to the existing guidance to cross-reference where this selected updates guidance supersedes the existing recommendations.  Subsequently, FDA will incorporate the elements of this final guidance into an anticipated revision of the entire Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems guidance.

Some updates the draft includes deal with material characterization, material composition, and biocompatibility.  The guidance can be found on FDA’s website.

For more information: www.fda.gov

Related Content

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
Feature | Cath Lab| November 24, 2015
November 24, 2015 — The U.S.
Boston Scientific, Watchman FLX, LAA closure device, CE mark, first European implants

Image courtesy of Boston Scientific

News | Left Atrial Appendage (LAA) Occluders| November 20, 2015
Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device
News | Cath Lab| November 10, 2015
TherOx Inc. announced it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE)...
Sponsored Content | Videos | TCT| November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Sponsored Content | Videos | TCT| November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
CSI, OPTIMIZE study, peripheral orbital atherectomy system, peripheral artery disease, PAD

Diamondback 360 orbital atherectomy system. Image courtesy of Cardiovascular Systems Inc.

News | Atherectomy Devices| November 03, 2015
Cardiovascular Systems Inc. (CSI) announced last week that the first two patients have been enrolled in its OPTIMIZE,...
Sponsored Content | Videos | Cath Lab| November 03, 2015
Guillaume Baillaird, CEO of ControlRad Systems, described how his company's technology can significantly reduce radia
Overlay Init